Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17427967 | 0.86 | ALDH1A1 (0.56) | ALDH1A1TSHRMAPTALOX15SMN1; SMN2 | |
| SCHEMBL6701215 | 0.85 | MAPT (0.58) | ALDH1A1TSHRMAPTSMN1; SMN2MEN1 | |
| SCHEMBL5010667 | 0.85 | HTR1A (0.61) | MAPTCHRNA7DRD2SIGMAR1 | |
| SCHEMBL20271984 | 0.85 | SMN1; SMN2 (0.69) | ALDH1A1TSHRMAPTUSP2SMN1; SMN2 | |
| SCHEMBL20271748 | 0.85 | ALDH1A1 (0.56) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL10759276 | 0.85 | TSHR (0.61) | ALDH1A1TSHRMAPTALOX15MEN1 | |
| SCHEMBL2661949 | 0.85 | ADRA2C (0.50) | ALDH1A1TSHRMAPTALOX15SMN1; SMN2 | |
| SCHEMBL31050602 | 0.84 | ALDH1A1 (0.53) | ALDH1A1TSHRMAPTUSP2ALOX15 | |
| SCHEMBL6701211 | 0.83 | ALDH1A1 (0.53) | ALDH1A1TSHRMAPTCHRNA7SMN1; SMN2 | |
| SCHEMBL8160104 | 0.83 | HTR1A (0.58) | MAPTDRD2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076982-A1 | Prodrugs of Cannbidiol [CBD]-Type Phytocannabinoids and a Process for Preparation Thereof | COUNCIL SCIENT IND RES (IN) | 2026-03-19 | — | — | US | disclosed |
| EP-4551241-A1 | PRODRUGS OF CANNBIDIOL [CBD]-TYPE PHYTOCANNABINOIDS AND A PROCESS FOR PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024009324-A1 | PRODRUGS OF CANNBIDIOL [CBD]-TYPE PHYTOCANNABINOIDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024009324-A1 | PRODRUGS OF CANNBIDIOL [CBD]-TYPE PHYTOCANNABINOIDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-01-11 | — | — | WO | disclosed |
| US-11851435-B2 | PTGR2 inhibitors and their use | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-12-26 | — | — | US | disclosed |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-09-07 | — | — | US | disclosed |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-09-07 | — | — | US | disclosed |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-09-07 | — | — | US | disclosed |
| US-20180360824-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-12-20 | — | — | US | disclosed |
| US-10022371-B2 | Procaspase-activating compounds and methods | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-07-17 | — | — | US | disclosed |
| US-20150231132-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2015-08-20 | — | — | US | disclosed |
| US-20150210659-A1 | PARTICULATE DRUG DELIVERY METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210659-A1 | PARTICULATE DRUG DELIVERY METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-07-30 | — | — | US | disclosed |
| US-8916705-B2 | Procaspase-activating compounds and compositions | The Board of Trustees of The University of Illilnois (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916705-B2 | Procaspase-activating compounds and compositions | The Board of Trustees of The University of Illilnois (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916705-B2 | Procaspase-activating compounds and compositions | The Board of Trustees of The University of Illilnois (US) | 2014-12-23 | — | — | US | disclosed |
| WO-2014022858-A1 | ENZYME-ACTIVATING COMPOUNDS AND COMPOSITIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-02-06 | — | — | WO | disclosed |
| US-20130096133-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND COMPOSITIONS | The Board of Trustees of the University lllinois (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096133-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND COMPOSITIONS | The Board of Trustees of the University lllinois (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096133-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND COMPOSITIONS | The Board of Trustees of the University lllinois (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076982-A1 | Prodrugs of Cannbidiol [CBD]-Type Phytocannabinoids and a Process for Preparation Thereof | CNR1, CNR2, CBR1 | ALDH1A1 1408/4885TSHR 1082/4885MAPT 3826/4885 |
| US-11851435-B2 | PTGR2 inhibitors and their use | PTGFR, PTGIR, PTGDR2 | ALDH1A1 1177/4885TSHR 270/4885MAPT 4487/4885 |
| US-20150210659-A1 | PARTICULATE DRUG DELIVERY METHODS | CASP3, BAX, CASP5 | ALDH1A1 2026/4885TSHR 4609/4885MAPT 2006/4885 |
| US-20150231132-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND METHODS | CASP3, CASP5, CASP6 | ALDH1A1 3075/4885TSHR 4827/4885MAPT 2776/4885 |
| US-20180360824-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND METHODS | CASP3, CASP5, CASP6 | ALDH1A1 3075/4885TSHR 4827/4885MAPT 2776/4885 |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | PTGFR, PTGIR, PTGDR2 | ALDH1A1 1177/4885TSHR 270/4885MAPT 4487/4885 |
| US-20130096133-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND COMPOSITIONS | CASP3, CASP5, CASP6 | ALDH1A1 3462/4885TSHR 4839/4885MAPT 2592/4885 |
| US-10022371-B2 | Procaspase-activating compounds and methods | CASP3, CASP5, CASP6 | ALDH1A1 3075/4885TSHR 4827/4885MAPT 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.